Biotech Express

Your legal springboard for start-up success

Biotech is booming, with global revenues expected to top $700bn by 2025. But the industry isn't just being defined by rapid growth. The radical revolution of the entire life sciences ecosystem is where the real change is being felt.

From a new focus on patients, regulators and lenders as partners and fresh pressures on affordability, to unfamiliar collaboration and investment models with non-traditional partners. 

So what do the leaders of the next revolution in Biotech really need to succeed?

At Pinsent Masons, we've been partnering with Biotech leadership teams for over 20 years, helping build long term success in their business by realising the value of their ideas and working to help commercialise them. 

For many businesses, the lack of robust legal documentation has meant that they don't have the solid foundations on which to grow the business and exploit the full potential of their ideas.

To help ensure that this doesn’t happen to you, our specialist team of life sciences and technology advisors has developed a suite of legal documents that all biotech start-ups can use to help them grow their business in the best way possible.

  • Register your interest via the registration link
  • One of our specialist advisors will be in contact with you to set up a meeting to discuss your requirements
  • In your one on one meeting with an advisor, they will work with you to tailor the suite of documents to your business' needs and agree on pricing
  • From this point onwards you will have regular access to our team of 100 sectors specialists spread across our offices globally


About Us

Our team brings you over 100 sector specialists spread across our offices globally, delivering award-winning, multi-disciplinary expertise through a range of technical backgrounds and experience that has been drawn from industry and regulatory bodies.

We can support every business-critical activity, from investor relations, planning and development to future-exit strategies and identifying key partners for sale or licensing. Our peerless corporate expertise helps to build a compelling story for investors when securing funding, too. But it’s actually the breadth of expertise we can offer that makes all the difference; from developing robust IP strategies to the regulatory support to get products to market, plus all of the associated challenges of building a nascent, high-growth enterprise. 

Aligning ourselves to the movement and direction of the industry, rather than the constraints of legal service lines, helps us deliver the kind of multi-disciplinary approach that works brilliantly for disruptive businesses

Meet the team

Show me all
Allistair Booth


Allistair is one of the lead partners in our Tier 1 ranked Life sciences & health transactional team.

Booth Allistair
Marc L. Holtorf

Rechtsanwalt, Fachanwalt für Gewerblichen Rechtsschutz, Partner, Head of German Intellectual Property

Marc leads Pinsent Masons’ German Intellectual Property Group and the German Life Sciences sector. He specialises in supporting pharmaceutical, medical device and other high-tech companies in navigating through the complex world of contentious and non-contentious intellectual property.

Marc Holtorf
Jules Fabre

Legal Director

Jules specialises in intellectual property, with a particular focus on patent matters in the Life Sciences and pharmaceutical sector. He has extensive experience handling complex French and cross border patent and SPC litigations, both in private practice and in-house.

Fabre Jules Sept_2019
Michael Finn


Michael specialises in the life sciences and TMT sectors. His practice focuses on complex domestic and international commercial disputes, contentious intellectual property matters, product liability, regulatory disputes and prosecutions, and administrative law challenges.

Finn Michael_Nov 2019
Inmaculada Castelló


Inmaculada is partner in the corporate team at Pinsent Masons in Madrid. She has particular experience in M&A, corporate investment and divestment transactions, and corporate restructuring.

Castell Inmaculada